Skip to content

Alterola Biotech, Inc.: 10-Q filed 2024-11-29

What Alterola Biotech, Inc. reported in its quarterly report filed 2024-11-29 (fiscal Q2 2025): 33 published measures, 92 facts as tagged in accession 0001477932-24-007731.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-29
Fiscal period
fiscal Q2 2025
Accession
0001477932-24-007731 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alterola Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-301,364,069USD
At 2024-03-313,663USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-303,615,314USD
At 2024-03-311,333,264USD
At 2021-05-28389,721USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-2,054,964USD
At 2024-03-31-1,329,601USD
At 2023-03-319,761,144USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-3082,720USD
At 2024-03-312,654USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-799,193USD92
2024-04-01 to 2024-09-30-1,453,940USD183
2023-07-01 to 2023-09-30-123,157USD92
2023-04-01 to 2023-09-30-854,887USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-1,067,729USD183
2023-04-01 to 2023-09-30-197,625USD183

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD92
2024-04-01 to 2024-09-300USD183
2023-07-01 to 2023-09-300USD92
2023-04-01 to 2023-09-300USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-04-01 to 2024-09-301,322,869USD183
2023-04-01 to 2023-09-3075,530USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-60,000USD183
2023-04-01 to 2023-09-3035,000USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-13,673,734USD
At 2024-03-31-12,416,075USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD92
2024-04-01 to 2024-09-300USD183
2023-07-01 to 2023-09-300USD92
2023-04-01 to 2023-09-300USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-477,231USD92
2024-04-01 to 2024-09-30-1,160,053USD183
2023-07-01 to 2023-09-30-123,157USD92
2023-04-01 to 2023-09-30-716,724USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-301,147,024USD
At 2024-03-313,663USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2024-09-30337,297USD92
2024-04-01 to 2024-09-300USD183
2023-07-01 to 2023-09-30337,297USD92
2023-04-01 to 2023-09-300USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-303,615,314USD
At 2024-03-311,333,264USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-30805,308USD
At 2024-03-31825,210USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-30477,231USD92
2024-04-01 to 2024-09-301,160,053USD183
2023-07-01 to 2023-09-30123,157USD92
2023-04-01 to 2023-09-30716,724USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-301,069USD
At 2024-03-311,009USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-3016,964USD92
2024-04-01 to 2024-09-3036,099USD183
2023-07-01 to 2023-09-300USD92
2023-04-01 to 2023-09-300USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-301,467,475,449shares
At 2024-03-311,382,662,949shares
At 2023-09-30778,031,952shares
At 2023-03-31807,047,948shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-3082,720USD
At 2024-03-312,654USD
At 2023-09-309,102USD
At 2023-03-318,890USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3010,226,499USD
At 2024-03-319,663,951USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2024-09-30-2,251,245USD
At 2024-03-31-1,329,601USD
At 2023-09-30-2,080,938USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-30461,989USD
At 2024-03-31362,451USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2023-03-31189,355USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-803,383USD92
2024-04-01 to 2024-09-30-1,458,130USD183
2023-07-01 to 2023-09-30-149,371USD92
2023-04-01 to 2023-09-30-881,101USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-3024,023USD92
2024-04-01 to 2024-09-3067,477USD183
2023-07-01 to 2023-09-3023,644USD92
2023-04-01 to 2023-09-3025,404USD183

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-321,962USD92
2024-04-01 to 2024-09-30-293,887USD183
2023-07-01 to 2023-09-300USD92
2023-04-01 to 2023-09-30-138,163USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-04-01 to 2024-09-300USD183
2023-04-01 to 2023-09-300USD183

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-04-01 to 2024-09-300USD183
2023-04-01 to 2023-09-300USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-04-01 to 2024-09-30200USD183
2023-04-01 to 2023-09-300USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-09-3060USD183
2023-04-01 to 2023-09-300USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-19,902USD183
2023-04-01 to 2023-09-30110,319USD183

Inspect the source

Entity
Alterola Biotech, Inc. / CIK 0001442999
Captured
2026-09-21T17:19:50.475Z
SEC response SHA-256
87a3a16f9156f52960516ff7604a147caa80abebfe964591df0bd913491df844

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001442999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))